Zip, That agreement from 8 years ago may have been amended at some point. Regardless, even if AMRN is due a large milestone payment for this approval I doubt if EddingPharm actually is able to pay it. (At least, without having done the long anticipated IPO.) I think the impact of this will be minimal for AMRN. If AMRN were bought by a BP then I think there are actions that the BP could take to help insure a successful launch of Vascepa in China. Perhaps this approval will be helpful to Denner in negotiating a BP BO of AMRN.